CN112513038B - 抑制creb结合蛋白(cbp) - Google Patents

抑制creb结合蛋白(cbp) Download PDF

Info

Publication number
CN112513038B
CN112513038B CN201980050022.XA CN201980050022A CN112513038B CN 112513038 B CN112513038 B CN 112513038B CN 201980050022 A CN201980050022 A CN 201980050022A CN 112513038 B CN112513038 B CN 112513038B
Authority
CN
China
Prior art keywords
alkyl
methyl
compound
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980050022.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN112513038A (zh
Inventor
S·E·R·席勒
托尔斯滕·赫伯茨
H·李
B·格瑞夫斯
S·米什克
A·V·韦斯特
A·爱立信
J·R·唐宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/051214 external-priority patent/WO2019055869A1/en
Application filed by Individual filed Critical Individual
Priority to CN202211658329.8A priority Critical patent/CN116178369A/zh
Publication of CN112513038A publication Critical patent/CN112513038A/zh
Application granted granted Critical
Publication of CN112513038B publication Critical patent/CN112513038B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980050022.XA 2018-06-29 2019-06-28 抑制creb结合蛋白(cbp) Active CN112513038B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211658329.8A CN116178369A (zh) 2018-06-29 2019-06-28 抑制creb结合蛋白(cbp)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862692593P 2018-06-29 2018-06-29
US62/692,593 2018-06-29
USPCT/US2018/051214 2018-09-14
PCT/US2018/051214 WO2019055869A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
PCT/US2018/051235 WO2019055877A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
USPCT/US2018/051235 2018-09-14
US201962819490P 2019-03-15 2019-03-15
US62/819,490 2019-03-15
PCT/US2019/039936 WO2020006483A1 (en) 2018-06-29 2019-06-28 Inhibiting creb binding protein (cbp)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211658329.8A Division CN116178369A (zh) 2018-06-29 2019-06-28 抑制creb结合蛋白(cbp)

Publications (2)

Publication Number Publication Date
CN112513038A CN112513038A (zh) 2021-03-16
CN112513038B true CN112513038B (zh) 2023-01-10

Family

ID=68987627

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980050022.XA Active CN112513038B (zh) 2018-06-29 2019-06-28 抑制creb结合蛋白(cbp)
CN202211658329.8A Pending CN116178369A (zh) 2018-06-29 2019-06-28 抑制creb结合蛋白(cbp)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211658329.8A Pending CN116178369A (zh) 2018-06-29 2019-06-28 抑制creb结合蛋白(cbp)

Country Status (26)

Country Link
US (3) US10870648B2 (https=)
EP (1) EP3998266A1 (https=)
JP (4) JP6781806B2 (https=)
KR (2) KR20250067962A (https=)
CN (2) CN112513038B (https=)
AU (3) AU2019295790B2 (https=)
BR (1) BR112020026783A2 (https=)
CA (1) CA3105099A1 (https=)
CY (1) CY1124762T1 (https=)
DK (1) DK3587418T3 (https=)
ES (1) ES2900105T3 (https=)
HR (1) HRP20211698T1 (https=)
HU (1) HUE056885T2 (https=)
IL (3) IL279734B2 (https=)
LT (1) LT3587418T (https=)
MA (1) MA50675B1 (https=)
MX (2) MX2023013508A (https=)
PL (1) PL3587418T3 (https=)
PT (1) PT3587418T (https=)
RS (1) RS62732B1 (https=)
SA (1) SA520420909B1 (https=)
SG (1) SG11202012767UA (https=)
SI (1) SI3587418T1 (https=)
SM (1) SMT202100636T1 (https=)
WO (1) WO2020006483A1 (https=)
ZA (2) ZA202100509B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279734B2 (en) * 2018-06-29 2024-11-01 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)
US12351577B2 (en) 2019-03-15 2025-07-08 Forma Therapeutics, Inc. Inhibiting cyclic AMP-responsive element-binding protein (CREB)
AU2020241709B2 (en) * 2019-03-15 2025-12-04 Forma Therapeutics, Inc. Compositions and methods for treating androgen receptor positive forms of cancer
IL299344A (en) 2020-06-25 2023-02-01 Tolremo Therapeutics Ag Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
AU2021298153A1 (en) 2020-06-25 2023-02-23 Tolremo Therapeutics Ag A combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for use in treating EGFR-mutant NSCLC
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120108581A1 (en) * 2009-03-27 2012-05-03 Kowa Company, Ltd Fused piperidine compound and pharmaceutical containing same
CN107531690A (zh) * 2014-11-27 2018-01-02 基因泰克公司 用作CBP和/或EP300抑制剂的4,5,6,7‑四氢‑1H‑吡唑并[4,3‑c]吡啶‑3‑胺化合物
US20180037590A1 (en) * 2010-05-26 2018-02-08 Sunovion Pharmaceuticals Inc. Substituted quinolines as pde-10 inhibitors
WO2019055869A1 (en) * 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404207A (en) 1981-11-06 1983-09-13 Riker Laboratories, Inc. Antimicrobial 8-substituted benzo [IJ]quinolizines
US5138089A (en) * 1986-06-27 1992-08-11 The Procter & Gamble Company Chromophores, sunscreen compositions and methods for preventing sunburn
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
JP5355838B2 (ja) 2000-11-20 2013-11-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キラルな光異性化可能な化合物
WO2003033517A1 (en) 2001-10-17 2003-04-24 The University Of British Columbia Ship 1 modulators
AU2002349477A1 (en) 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
IN2003CH00929A (https=) 2003-11-13 2008-10-06
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
JP2009520038A (ja) 2005-12-19 2009-05-21 ジェネンテック・インコーポレーテッド ピリミジンキナーゼインヒビター
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
CN101489544A (zh) 2006-05-09 2009-07-22 海玛奎斯特医药公司 治疗血液病的方法
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
CA2574531C (en) 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
IN2014MN02330A (https=) 2007-06-21 2015-08-14 Wistar Inst
WO2009000413A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
JP5223864B2 (ja) 2007-06-27 2013-06-26 大正製薬株式会社 １１β−ＨＳＤ１阻害活性を有する化合物
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
AU2009330686B2 (en) 2008-06-16 2014-07-03 The Ohio State University Research Foundation Compounds for the treatment of cancer
WO2010118208A1 (en) 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
CN102459271B (zh) 2009-04-15 2014-07-02 Jw制药公司 回折模拟物的新化合物及其制备方法和用途
CN102459248A (zh) 2009-05-26 2012-05-16 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧杂环庚三烯以及它们使用与制造方法
WO2010138490A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
US9005670B2 (en) 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
MX2012010115A (es) 2010-03-01 2013-02-26 Gtx Inc Compuestos para el tratamiento de cancer.
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
EP2678050B1 (en) 2011-02-24 2020-10-14 Emory University Noggin blocking compositions for ossification and methods related thereto
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013148114A1 (en) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
US9211333B2 (en) 2012-06-05 2015-12-15 Hong Kong Baptist University Anti-cancer agents synthesized based on miliusane compounds
IN2015DN02008A (https=) 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
EP3010918B1 (en) 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
CA2915838C (en) 2013-06-21 2023-04-18 Zenith Epigenetics Corp. Bicyclic bromodomain inhibitors
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
DE102013215912B3 (de) 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
JP6553632B2 (ja) 2013-11-18 2019-07-31 フォーマ セラピューティクス，インコーポレイテッド Ｂｅｔブロモドメイン阻害剤としてのテトラヒドロキノリン組成物
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
WO2016044694A1 (en) 2014-09-19 2016-03-24 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
EP3242878B1 (en) 2015-01-08 2020-10-14 Impetis Biosciences Ltd. Bicyclic compounds, compositions and medicinal applications thereof
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
AU2017263574B2 (en) 2016-05-12 2022-11-17 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
MA45122A (fr) 2016-05-24 2019-04-10 Constellation Pharmaceuticals Inc Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
EP3612522A4 (en) * 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
IL279734B2 (en) * 2018-06-29 2024-11-01 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120108581A1 (en) * 2009-03-27 2012-05-03 Kowa Company, Ltd Fused piperidine compound and pharmaceutical containing same
US20180037590A1 (en) * 2010-05-26 2018-02-08 Sunovion Pharmaceuticals Inc. Substituted quinolines as pde-10 inhibitors
CN107531690A (zh) * 2014-11-27 2018-01-02 基因泰克公司 用作CBP和/或EP300抑制剂的4,5,6,7‑四氢‑1H‑吡唑并[4,3‑c]吡啶‑3‑胺化合物
WO2019055869A1 (en) * 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300

Also Published As

Publication number Publication date
AU2023226653B2 (en) 2025-09-04
US12378242B2 (en) 2025-08-05
SG11202012767UA (en) 2021-01-28
SMT202100636T1 (it) 2022-01-10
BR112020026783A2 (pt) 2021-03-30
US10870648B2 (en) 2020-12-22
ZA202210560B (en) 2025-12-17
JP2020002135A (ja) 2020-01-09
MA50675B1 (fr) 2021-09-30
JP2021042255A (ja) 2021-03-18
LT3587418T (lt) 2021-11-25
MA50675A (fr) 2021-04-07
IL279734B1 (en) 2024-07-01
PL3587418T3 (pl) 2022-02-21
HUE056885T2 (hu) 2022-03-28
MX2020014303A (es) 2021-03-25
JP2025094157A (ja) 2025-06-24
IL313466B1 (en) 2025-07-01
JP6781806B2 (ja) 2020-11-04
HRP20211698T1 (hr) 2022-02-18
DK3587418T3 (da) 2021-10-11
CY1124762T1 (el) 2022-07-22
JP2020128426A (ja) 2020-08-27
EP3998266A1 (en) 2022-05-18
US20220162207A1 (en) 2022-05-26
ES2900105T3 (es) 2022-03-15
KR102805503B1 (ko) 2025-05-09
ZA202100509B (en) 2022-12-21
IL279734A (en) 2021-03-01
SI3587418T1 (sl) 2022-03-31
IL313466A (en) 2024-08-01
US20200299295A1 (en) 2020-09-24
AU2025210762A1 (en) 2025-08-21
RS62732B1 (sr) 2022-01-31
PT3587418T (pt) 2021-12-02
AU2019295790B2 (en) 2023-07-13
IL321337A (en) 2025-08-01
AU2019295790A1 (en) 2021-01-28
US11254674B2 (en) 2022-02-22
JP7017801B2 (ja) 2022-02-09
KR20250067962A (ko) 2025-05-15
MX2023013508A (es) 2023-12-13
WO2020006483A1 (en) 2020-01-02
IL279734B2 (en) 2024-11-01
SA520420909B1 (ar) 2024-11-12
CN112513038A (zh) 2021-03-16
IL313466B2 (en) 2025-11-01
CA3105099A1 (en) 2020-01-02
AU2023226653A1 (en) 2023-09-21
KR20210025631A (ko) 2021-03-09
CN116178369A (zh) 2023-05-30
US20200002332A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
CN112513038B (zh) 抑制creb结合蛋白(cbp)
TWI795440B (zh) 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
CN105884780B (zh) 多环化合物、其药物组合物及应用
KR20180099787A (ko) Btk 키나아제 억제제의 결정질 형태 및 이의 제조 방법
EP3587418B1 (en) Inhibitors of creb binding protein (cbp)
RU2803290C2 (ru) Ингибирование creb-связывающего белка (cbp)
HK40074924A (en) Inhibiting creb binding protein (cbp)
CN113874017A (zh) 抑制环amp-应答元件结合蛋白(creb)
RU2831142C2 (ru) Ингибирование циклического amp-чувствительного элемент-связывающего белка (creb)
HK40018316B (en) Inhibitors of creb binding protein (cbp)
HK40018316A (en) Inhibitors of creb binding protein (cbp)
MD3587418T2 (ro) Inhibitori ai proteinei de legare CREB (CBP)
BR122025003836A2 (pt) Composto e composição farmacêutica
HK40123135A (zh) 抑制环amp-应答元件结合蛋白(creb)
EA046876B1 (ru) Ингибирование creb-связывающего белка (cbp)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant